Total Payments
$698.21
2024 Payments
$183.78
Companies
16
Transactions
21
Medicare Patients
16,018
Medicare Billing
$5.0M
Payment Breakdown by Category
Food & Beverage$369.94 (53.0%)
Education$328.27 (47.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $369.94 | 15 | 53.0% |
| Education | $328.27 | 6 | 47.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $99.95 | 1 | $0 (2018) |
| Incyte Corporation | $99.95 | 1 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $84.95 | 1 | $0 (2021) |
| Foundation Medicine, Inc. | $84.93 | 1 | $0 (2017) |
| Genentech, Inc. | $49.54 | 2 | $0 (2018) |
| PFIZER INC. | $46.27 | 2 | $0 (2024) |
| Covidien LP | $41.04 | 2 | $0 (2019) |
| ABBVIE INC. | $39.67 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $35.23 | 2 | $0 (2024) |
| Exelixis Inc. | $27.96 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $183.78 | 9 | ABBVIE INC. ($39.67) |
| 2023 | $30.65 | 2 | PFIZER INC. ($17.70) |
| 2021 | $208.32 | 4 | Incyte Corporation ($99.95) |
| 2019 | $41.04 | 2 | Covidien LP ($41.04) |
| 2018 | $149.49 | 3 | Astellas Pharma US Inc ($99.95) |
| 2017 | $84.93 | 1 | Foundation Medicine, Inc. ($84.93) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| Category: Oncology | ||||||
| 10/30/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: BioOncology | ||||||
| 08/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.94 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.95 | General |
| Category: Hematology | ||||||
| 08/17/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2021 | SANOFI-AVENTIS U.S. LLC | ELITEK (Biological) | Education | In-kind items and services | $84.95 | General |
| Category: Oncology | ||||||
| 06/22/2021 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/02/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2019 | Covidien LP | Palindrome (Device) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Dialysis Catheters | ||||||
| 10/08/2019 | Covidien LP | Palindrome (Device) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Dialysis Catheters | ||||||
| 04/18/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 01/27/2018 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: BioOncology | ||||||
| 01/14/2018 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: BioOncology | ||||||
| 09/06/2017 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONFOCUS, FOUNDATIONACT | Food and Beverage | In-kind items and services | $84.93 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 64 | 3,799 | 86,263 | $4.2M | $1.4M |
| 2022 | 66 | 4,014 | 99,455 | $3.8M | $1.2M |
| 2021 | 62 | 3,689 | 89,344 | $2.6M | $848,719 |
| 2020 | 65 | 4,516 | 129,125 | $4.3M | $1.5M |
Total Patients
16,018
Total Services
404,187
Medicare Billing
$5.0M
Procedure Codes
257
All Medicare Procedures & Services
257 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 11,203 | $1.4M | $485,678 | 34.7% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 11 | 6,960 | $821,280 | $306,609 | 37.3% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 6,050 | $526,350 | $215,287 | 40.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 737 | 1,481 | $407,275 | $127,646 | 31.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 3,420 | $119,700 | $62,768 | 52.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 13,960 | $125,640 | $32,505 | 25.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 108 | 321 | $96,000 | $30,096 | 31.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 172 | 305 | $68,625 | $18,219 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 96 | $33,600 | $12,179 | 36.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 481 | 1,153 | $46,120 | $11,884 | 25.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 12 | 12,750 | $63,750 | $11,231 | 17.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 513 | 1,411 | $28,220 | $10,709 | 37.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 64 | 187 | $28,050 | $8,506 | 30.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 67 | 134 | $22,110 | $7,824 | 35.4% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 20 | 380 | $32,300 | $6,545 | 20.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $17,625 | $5,302 | 30.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 90 | 472 | $25,960 | $5,295 | 20.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 19 | 45 | $15,750 | $5,166 | 32.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 35 | 104 | $15,600 | $4,823 | 30.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 91 | $15,925 | $4,771 | 30.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 21 | 61 | $11,956 | $3,729 | 31.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 63 | 154 | $10,934 | $3,254 | 29.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 43 | 177 | $7,788 | $2,632 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $8,400 | $2,356 | 28.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 69 | 227 | $13,620 | $2,290 | 16.8% |
About Dr. Robert Langdon, M.D
Dr. Robert Langdon, M.D is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689654618.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Langdon, M.D has received a total of $698.21 in payments from pharmaceutical and medical device companies, with $183.78 received in 2024. These payments were reported across 21 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($369.94).
As a Medicare-enrolled provider, Langdon has provided services to 16,018 Medicare beneficiaries, totaling 404,187 services with total Medicare billing of $5.0M. Data is available for 4 years (2020–2023), covering 257 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Omaha, NE
- Active Since 01/17/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1689654618
Products in Payments
- ELITEK (Biological) $84.95
- FOUNDATIONONE (Device) $84.93
- TECENTRIQ (Biological) $49.54
- IBRANCE (Drug) $46.27
- Palindrome (Device) $41.04
- OPDUALAG (Drug) $35.23
- CABOMETYX (Drug) $27.96
- EPKINLY (Drug) $21.17
- FOTIVDA (Drug) $20.00
- VENCLEXTA (Drug) $18.50
- Itovebi (Biological) $17.09
- BRAFTOVI (Drug) $15.26
- Pomalyst (Drug) $12.95
- TAZVERIK (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Margaret Block, M.d, M.D
Hematology & Oncology — Payments: $444,214
Hematology & Oncology $444,214
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519